Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It provides follicle‑stimulating and luteinizing hormone activity to treat infertility in women and stimulate spermatogenesis in men with hypogonadotropic hypogonadism.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company provides dedicated logistics, cold‑chain management where required, and comprehensive documentation to support import and distribution.

Menopur is a gonadotropin used in reproductive medicine to stimulate follicular development and hormone production. - Anovulatory women: induces ovulation by providing exogenous FSH and LH activity, enhancing the likelihood of natural conception. - Assisted reproductive technology cycles (IVF, ICSI): promotes development of multiple ovarian follicles, facilitating controlled ovarian hyperstimulation and optimal egg retrieval. - Men with hypogonadotropic hypogonadism: stimulates testicular Leydig and Sertoli cell function to increase spermatogenesis and improve male fertility outcomes.

Menopur may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort or redness at the injection site. - Abdominal discomfort or bloating: transient gastrointestinal upset. - Headache: mild to moderate intensity. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): potentially severe fluid shift and ovarian enlargement. - Multiple pregnancy: increased risk of twins or higher-order gestations. - Severe allergic reaction (anaphylaxis): rare but may include rash, swelling, and respiratory distress.

When using Menopur, clinicians should observe several precautionary measures to minimize risks and optimize treatment outcomes. - Monitor ovarian response: perform serial ultrasounds and estradiol measurements to detect excessive stimulation. - Risk of OHSS: assess patient risk factors and adjust dose or discontinue if signs appear. - Contraindicated in pregnancy: avoid use in confirmed pregnancy. - Hormone‑sensitive tumors: do not use in patients with estrogen‑dependent neoplasms. - Thyroid disease: correct underlying thyroid dysfunction before initiating therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications that affect hormonal balance or coagulation, requiring careful management.

Major Interactions (Avoid): - GnRH agonists: may blunt the intended gonadotropin response. - Oral contraceptives: suppress endogenous gonadotropins, reducing efficacy. - Chemotherapy agents: can impair gonadal function and counteract treatment goals.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may alter ovarian response; monitor thyroid levels. - Anticoagulants: increased risk of ovarian cyst rupture; observe for bleeding. - Corticosteroids: may affect hormone metabolism; adjust monitoring as needed.